Imatinib resistance in chronic myelogenous leukemia is frequently associated with either ABL kinase mutations or with secondary rearrangements of the BCR-ABL

被引：0
|
作者：
Yin, C [1 ]
Luthra, R [1 ]
Cortes, J [1 ]
Reeves, N [1 ]
Hayes, K [1 ]
Glassman, A [1 ]
Kantarjian, H [1 ]
Jones, D [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF MOLECULAR DIAGNOSTICS | 2004年 / 6卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
H8
引用
收藏
页码：416 / 416
页数：1
相关论文
共 50 条
  • [41] MOLECULAR CONSEQUENCES OF THE BCR-ABL TRANSLOCATION IN CHRONIC MYELOGENOUS LEUKEMIA
    SAWYERS, CL
    LEUKEMIA & LYMPHOMA, 1993, 11 : 101 - 103
  • [42] Bcr-Abl and inhibition of apoptosis in chronic myelogenous leukemia cells
    Fernandez-Luna, JL
    APOPTOSIS, 2000, 5 (04) : 315 - 318
  • [43] Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia
    O'Hare, Thomas
    Eide, Christopher A.
    Deininger, Michael W. N.
    BLOOD, 2007, 110 (07) : 2242 - 2249
  • [44] Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate
    Mats Hardling
    Yuan Wei
    Lars Palmqvist
    Birgitta Swolin
    Dick Stockelberg
    Bengt Gustavsson
    Kerstin Ekeland-Sjöberg
    Hans Wadenvik
    Anne Ricksten
    Medical Oncology, 2004, 21 : 349 - 358
  • [45] BCR-ABL independent clones in Imatinib mesylate resistant chronic myelogenous leukemia patients.
    Donato, NJ
    Wu, JY
    Stapley, J
    Hui, L
    Arlinghaus, RB
    Aggarwal, B
    Albitar, M
    Pathak, S
    Hayes, KJ
    Talpaz, M
    BLOOD, 2002, 100 (11) : 371A - 371A
  • [46] Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate
    Hardling, M
    Wei, Y
    Palmqvist, L
    Swolin, B
    Stockelberg, D
    Gustavsson, B
    Ekeland-Sjöberg, K
    Wadenvik, H
    Ricksten, A
    MEDICAL ONCOLOGY, 2004, 21 (04) : 349 - 358
  • [47] Efficacy of dasatinib in chronic phase chronic myelogenous leukemia patients after imatinib failure according to baseline BCR-ABL mutations
    Hochhaus, A.
    Branford, S.
    Radich, J.
    Mueller, M. C.
    Shah, N.
    Erben, P.
    Ernst, T.
    Acevedo, M.
    Nicaise, C.
    Hughes, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [48] Efficacy of dasatinib in chronic phase chronic myelogenous leukemia patients after imatinib failure according to baseline BCR-ABL mutations
    Mueller, M. C.
    Branford, S.
    Radich, J.
    Shah, N.
    Erben, P.
    Ernst, T.
    Acevedo, M.
    Nicaise, C.
    Hughes, T.
    Hochhaus, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 127 - 127
  • [49] ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia
    Ernst, Thomas
    Hoffmann, Jana
    Erben, Philipp
    Hanfstein, Benjamin
    Leitner, Armin
    Hehlmann, Ruediger
    Hochhaus, Andreas
    Mueller, Martin C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 (09): : 1389 - 1393
  • [50] Examination of point mutations within the ABL kinase domain of Bcr-Abl fusion gene in Chinese patients with chronic myeloid leukemia who develop imatinib resistance
    Yang, Dongguang
    Zhang, Ri
    Gang, Honglin
    Gu, Jian
    Cen, Jian Nong
    BLOOD, 2007, 110 (11) : 214B - 215B
12345